Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
P/E ratio for Biora Therapeutics, Inc. (BIOR)
P/E ratio as of 2023: -1.72
According to Biora Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.72. At the end of 2022 the company had a P/E ratio of -5.15.
P/E ratio history for Biora Therapeutics, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.72 |
| 2022 | -5.15 |
| 2021 | -11.26 |
| 2020 | -15.38 |
| 2019 | -40.91 |
| 2018 | -27.40 |